Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) [Phase 2]
Phase 2 substudy MK-3475-01I/KEYMAKER-U01I evaluating investigational pembrolizumab-based therapy in previously treated stage IV squamous no…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor [Phase 3]
Phase 3 trial update indicates OSE2101, a therapeutic cancer vaccine, is being studied in non-small cell lung cancer patients with secondary…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) [Phase 3]
This entry describes an ongoing Phase 3 clinical trial evaluating pembrolizumab in combination with berahyaluronidase alfa (MK-3475A) for ne…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer [Phase 2]
A Phase 2 clinical trial is evaluating hippocampus-sparing radiotherapy in combination with osimertinib for symptomatic brain metastases in …
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
This clinical trial update discusses a Pfizer-sponsored study evaluating dacomitinib in patients with non-small cell lung cancer, with the t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-31EMA Authorised: Alecensa (alectinib hydrochloride) — Roche Registration GmbH
The European Medicines Agency authorised Alecensa (alectinib hydrochloride) for treatment of non-small cell lung cancer under Roche Registra…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% [Phase 3]
This is a Phase 3 clinical trial update describing a study that compares nivolumab plus relatlimab with chemotherapy against pembrolizumab p…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer [Phase 1]
This Phase 1 trial update reports on the safety and efficacy of a neoantigen-based personalized immunotherapy used as consolidation therapy …
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types [Phase 1]
IDEAYA Biosciences is conducting a Phase 1 study of IDE034 in adults with multiple locally advanced or metastatic solid tumors; the trial is…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab [Phase 2]
A Phase 2 clinical trial investigating neoadjuvant low-dose stereotactic body radiotherapy combined with ipilimumab and nivolumab for non-sm…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer [Phase 1, Phase 2]
A clinical trial update for AU-007, a monoclonal antibody that binds IL-2 and inhibits IL-2Rα binding, being studied in unresectable locally…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers [Phase 1]
Phase 1 study of AB598 as monotherapy and in combination across multiple advanced cancers is ongoing, with status active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) [Phase 2]
A Phase 2 study evaluating pembrolizumab (MK-3475) in combination with investigational agents for resectable non-small cell lung cancer is c…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II) [Phase 2]
A Phase II clinical trial evaluating Y-90 labeled Fibroblast Activation Protein Inhibitor therapy in patients with non-small cell lung cance…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC [Phase 1]
Phase 1 clinical trial update for CD40L-augmented tumor-infiltrating lymphocytes in EGFR, ALK, ROS1 or HER2-driven non-small cell lung cance…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [Phase 3]
Global Phase III trial evaluating Rilvegostomig or pembrolizumab plus chemotherapy as first-line treatment for metastatic squamous non-small…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer [NA]
A clinical trial is planned to evaluate a multimodal outpatient supervised physical activity program designed to improve chemotherapy tolera…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer [Phase 1]
A Phase 1 trial from Emory University is evaluating the combination of MRX-2843 and osimertinib in adults with advanced EGFR-mutant non-smal…
-
EMA approval · 2026-03-30EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
The European Medicines Agency authorized Tecentriq (atezolizumab) by Roche Registration GmbH for multiple cancer indications, including non-…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Safety and Efficacy of Xalkori ROS1
This clinical trial update summarizes safety and efficacy findings for crizotinib (Xalkori) in patients with ROS1-rearranged non-small cell …
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer [Phase 1]
This Clinical Trials Update describes a Phase 1 study of an Fc-engineered anti-CTLA-4 monoclonal antibody by Agenus in patients with advance…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations [Phase 3]
Takeda's TAK-788 is being studied as a first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations in a Phase 3 trial agai…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC [Phase 1]
A Phase 1 trial is evaluating a KRAS-targeted vaccine in combination with nivolumab and ipilimumab for non-small cell lung cancer. The study…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS [Phase 2]
A Phase 2 trial compares durvalumab plus tremelimumab with chemotherapy against pembrolizumab plus chemotherapy in metastatic non-squamous n…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Immune and Genomic Markers in ALK+ NSCLC
A Massachusetts General Hospital-led clinical trial on immune and genomic markers in ALK-positive non-small cell lung cancer is currently ac…